Online inquiry

IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2028MR)

This product GTTS-WQ2028MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2028MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8059MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ13379MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ10546MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ14478MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ1661MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACT-017
GTTS-WQ3279MR IVTScrip™ mRNA-Anti-alpha toxin&lukE, ASN-1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ8530MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Hu3F8
GTTS-WQ8962MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW